News Image

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

Provided By GlobeNewswire

Last update: Nov 12, 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET

Read more at globenewswire.com

PYXIS ONCOLOGY INC

NASDAQ:PYXS (2/21/2025, 8:00:01 PM)

After market: 1.2882 +0.01 (+0.64%)

1.28

-0.08 (-5.88%)



Find more stocks in the Stock Screener

Follow ChartMill for more